Comparative Assessment of Clinically Utilized CD20-directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK cell, Monocyte and Macrophage Properties

CD20 is a widely validated, B cell specific target for therapy in B cell malignancies. Rituximab is an anti-CD20 antibody that when combined with chemotherapy prolongs survival of CLL patients. Ofatumumab and GA101 (obinutuzumab) are CD20-directed antibodies now being developed as alternative agents...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rafiq, Sarwish, Butchar, Jonathon P., Cheney, Carolyn, Mo, Xiaokui, Trotta, Rossana, Caligiuri, Michael, Jarjoura, David, Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3631574/
https://ncbi.nlm.nih.gov/pubmed/23418626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1202588
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak